Hepatocellular carcinoma in developing countries: Prevention, diagnosis and treatment

World Journal of Hepatology

Volumn 4, Issue 3, 2012, Pages 99-104

  Kew, Michael C ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

fetoprotein; Aflatoxin B1; Hepatic resection; Hepatic transplantation; Hepatitis B virus infection; Sorafenib

Indexed keywords

EID: 84865343239     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v4.i3.99     Document Type: Article

References (42)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Establishment of world-wide burden of cancer in 2008: GLOBCAN 2008. Int J Cancer 2010; 127: 2893-2917
2. Kew MC. Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. Pathol Biol (Paris) 2010; 58: 273-277
3. Beasely RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and HBV: a prospective study of 22,000 men in Taiwan. Lancet 1981; 22: 1129-1133
4. Wild CP, Gong YY. Mycotoxins and human disease: a largely ignored global health issue. Carcinogenesis 2010; 31: 71-82
5. Kew MC. Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver Int 2003; 23: 405-409
6. Bile K, Aden C, Norder H, Magnius L, Lindberg G, Nilsson Z. Important role of hepatitis C virus infection as a cause of chronic liver disease in Somalia. Scand J Dig Dis 1993; 25: 559-564
7. Yu SZ, Chen G. Blue-green algae toxins and liver cancer. China J Cancer Res 1994; 6: 9-17
8. Zhou TL, Yu SZ. Laboratory study on the relationship between drinking water andhepatoma. Quantitative evaluation using GGT method. Zhonghua Yu Fang Yi Xue Za Zhi 1990; 234: 203-205
9. WHO/IVB 2008 database accessed Sept 4, 2009. Available from URL: http://www.who.int/immunization_momitoring/data/year_vaccineintroduction.xis
10. WHO/UNICEF estimates. Available from URL: http://www.who.int/immunizationmonitoring/en/globalsummary/countryprofileselerct.cfm
11. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, Chu HC, Wu TC, Yang SS, Kuo HS, Chen DS. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009; 101: 1348-1355
12. Chang MH, Chen TH, Hsu HM, Wu TC, Kong MS, Liang DC, Ni YH, Chen CJ, Chen DS. Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems. Clin Cancer Res 2005; 11: 7953-7957
13. Kew M, François G, Lavanchy D, Margolis H, Van Damme P, Grob P, Hallauer J, Shouval D, Leroux-Roels G, Meheus A. Prevention of hepatitis C virus infection. J Viral Hepat 2004; 11: 198-205
14. Turner PC, Sylla A, Gong YY, Diallo MS, Sutcliffe AE, Hall AJ, Wild CP. Reduction in exposure to carcinogenic aflatoxins by post harvest intervention measures in west Africa: a community-based intervention study. Lancet 2005; 365: 1950-1956
15. Sudakin DL. Dietary aflatoxin exposure and chemoprevention of cancer: a clinical review. J Toxicol Clin Toxicol 2003; 41: 195-204
16. Kensler TW, Qian GS, Chen JG, Groopman JD. Translational strategies for cancer prevention in liver. Nat Rev Cancer 2003; 3: 321-329
17. Yu SZ. Primary prevention of hepatocellular carcinoma. J Gastroenterol Hepatol 1995; 10: 674-682
18. Alpert E. Human a1-fetoprotein. In Hepatocellular Carcinoma. Okuda K, Peters RL, editors. New York: Wiley, 1976: 353-359
19. Kew MC. Tumour markers of hepatocellular carcinoma. J Gastroenterol Hepatol 1989; 4: 373-384
20. Tsai JF, Chang WY, Jeng JE, Ho MS, Lin ZY, Tsai JH. Frequency of raised alpha-fetoprotein level among Chinese patients with hepatocellular carcinoma related to hepatitis B and C. Br J Cancer 1994; 69: 1157-1159
21. Johnson PJ. Role of alpha-fetoprotein in the diagnosis and management of hepatocellular carcinoma. J Gastroenterol Hepatol 1999; 14 Suppl: S32-S36
22. Kew MC, Dos Santos HA, Sherlock S. Diagnosis of primary cancer of the liver. Br Med J 1971; 4: 408-411
23. Kew MC, Popper H. Relationship between hepatocellular carcinoma and cirrhosis. Semin Liver Dis 1984; 4: 136-146
24. Kew MC. Unusual clinical manifestations of hepatocellular carcinoma. Clin Adv Haematol Oncol 2005; 3: 577-583
25. Clain D, Wartnaby K, Sherlock S. Abdominal arterial bruits in liver disease. Lancet 1966; 2: 516-519
26. Levy JI, Geddes EW, Kew MC. The chest radiograph in primary liver cancer. S Afr Med J 1976; 50: 1323-1326
27. Sanders CF. The plain chest radiograph in 75 cases of primary carcinoma of the liver. Clin Radiol 1968; 19: 341-346
28. Purves LR. a-fetoprotein and the diagnosis of liver cell cancer. In: Liver Cell cancer. Cameron CM, Linsell DA, Warwick GP, editors. Amsterdam: Elsevier, 1976: 61-79
29. Ebara M, Ohto M, Shinagawa T, Sugiura N, Kimura K, Matsutani S, Morita M, Saisho H, Tsuchiya Y, Okuda K. Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. A study in 22 patients. Gastroenterology 1986; 90: 289-298
30. Okazaki N, Yoshino M, Yoshida T, Suyzuki M, Moriyama N, Takayasu K, Makuuchi M, Yamazeki S, Hasegawa H, Noguchi M. Evaluation of the prognosis of small hepatocellular carcinoma based on tumor volume doubling time. Cancer 1989; 63: 2207-2210
31. Harrison NW, Dhru D, Primack A, Bhana D, Kyalwazi SK. The surgical management of primary hepatocellular carcinoma in Uganda. Br J Surg 1973; 60: 565-569
32. Maraj R, Kew MC, Hyslop RJ. Resectability rate of hepatocellular carcinoma in rural southern Africans. Br J Surg 1988; 75: 335-338
33. Foster JH, Berman MM. Solid liver tumors. Major Probl Clin Surg 1977; 22: 1-342
34. Okuda K, Ohsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakojima Y, Onishin K. Natural history of hepatocellular carcinoma and relation to treatment. Cancer 1985; 56: 918-928
35. Kew MC, Paterson AC. Unusual clinical presentations of hepatocellular carcinoma. Trop Gastroenterol 1985; 6: 10-22
36. Steiner PE. Cancer of the liver and cirrhosis in Trans-Saharan Africa and the United States of America. Cancer 1960; 13: 1085-1166
37. Davies JNP. Cancer of the Liver in Trans-Saharan Africa. UICC Monographs, No. 1. Berlin: Springer-Verlag, 1961
38. Okuda K. Clinical presentation and natural history of hepatocellular carcinoma and other liver cancers. In: Liver Cancer. Okuda K, Tabor E, editors. New York: Churchill Livingstone, 1997: 1-12
39. Mendizabal M, Reddy KR. Current management of hepatocellular carcinoma. Med Clin North Am 2009; 93: 885-900, viii
40. Imamura H, Matsuyama Y, Tanaka E, Ohkuba T, Hasegawa K, Miyagawa S, Sugamura Y, Minagawa M, Takayama T, Kawasaki S, Makuuchi M. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003; 38: 200-207
41. Ijichi M, Takayama T, Matsumura M, Shiratori Y, Omata M, Makuuchi M. alpha-Fetoprotein mRNA in the circulation as a predictor of postsurgical recurrence of hepatocellular carcinoma: a prospective study. Hepatology 2002; 35: 853-860
42. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48: 1312-1327